1014 GMT - Haleon's earnings-per-share beat signals an turning point, Barclays analysts say in a note. The British consumer-health giant's historical lack of EPS delivery has been a key investor complaint which should ease now after its 2H topped consensus by 6%, Barclays says. "Given recent strength in Haleon's share price we could see some profit taking first thing this morning, but the robust topline and EPS delivery confirm our thesis that Haleon is establishing a track record as a steady compounder," the analysts say. Haleon's 2025 guidance is in line with expectations, but its 2H weighting comes as a surprise, they add. Shares are down 3.1% at 38.33 pounds. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
February 27, 2025 05:14 ET (10:14 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.